BioTelemetry (BEAT) Competitors

Pulmonx (NASDAQ:LUNG) and BioTelemetry (NASDAQ:BEAT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, community ranking, earnings, risk, institutional ownership, dividends and valuation.

Which has more volatility & risk, LUNG or BEAT?

Pulmonx has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, BioTelemetry has a beta of -0.71, indicating that its share price is 171% less volatile than the S&P 500.

Is LUNG or BEAT more profitable?

BioTelemetry has a net margin of 0.00% compared to Pulmonx's net margin of -67.31%. Pulmonx's return on equity of -55.36% beat BioTelemetry's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-67.31%	-55.36%	-33.53%
BioTelemetry	N/A	-175.50%	-154.96%

Do institutionals & insiders have more ownership in LUNG or BEAT?

91.0% of Pulmonx shares are held by institutional investors. Comparatively, 7.8% of BioTelemetry shares are held by institutional investors. 6.8% of Pulmonx shares are held by insiders. Comparatively, 20.9% of BioTelemetry shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Does the MarketBeat Community believe in LUNG or BEAT?

BioTelemetry received 352 more outperform votes than Pulmonx when rated by MarketBeat users. Likewise, 63.37% of users gave BioTelemetry an outperform vote while only 47.56% of users gave Pulmonx an outperform vote.

Company	Underperform	Outperform
Pulmonx	Outperform Votes 39 47.56%	Underperform Votes 43 52.44%
BioTelemetry	Outperform Votes 391 63.37%	Underperform Votes 226 36.63%

Which has higher valuation and earnings, LUNG or BEAT?

BioTelemetry has lower revenue, but higher earnings than Pulmonx. BioTelemetry is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$83.79M	1.81	-$60.84M	-$1.44	-2.62
BioTelemetry	N/A	N/A	-$14.64M	-$0.68	-2.62

Does the media favor LUNG or BEAT?

In the previous week, Pulmonx had 15 more articles in the media than BioTelemetry. MarketBeat recorded 17 mentions for Pulmonx and 2 mentions for BioTelemetry. Pulmonx's average media sentiment score of 0.57 beat BioTelemetry's score of 0.00 indicating that Pulmonx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulmonx	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioTelemetry	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts prefer LUNG or BEAT?

Pulmonx currently has a consensus price target of $12.07, indicating a potential upside of 220.20%. BioTelemetry has a consensus price target of $8.00, indicating a potential upside of 348.18%. Given BioTelemetry's stronger consensus rating and higher possible upside, analysts clearly believe BioTelemetry is more favorable than Pulmonx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
BioTelemetry	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Pulmonx beats BioTelemetry on 9 of the 17 factors compared between the two stocks.